The FMDV VLP mRNA vaccine provided a 100% protection rate against FMDV challenge in guinea pigs, comparable to traditional inactivated vaccines, while stimulating robust humoral and cellular immunity.
Does an FMD VLP mRNA vaccine induce strong humoral and cellular immunity and provide protection in animal models?
A novel FMD VLP mRNA vaccine effectively stimulates both humoral and cellular immune responses and provides protective efficacy comparable to traditional inactivated vaccines in animal models.
Tasa de eventos absoluta: 100% vs 0%
Foot-and-mouth disease (FMD) is a major animal infectious disease that has garnered significant international attention. Currently, conventional inactivated vaccines and virus-like particle (VLP) vaccines primarily induce protective immune responses through the generation of neutralizing antibodies. However, these vaccines exhibit limited activation of cellular immunity and offer short-term immune persistence. Furthermore, inactivated vaccines raise certain biosafety concerns. In this study, an FMD mRNA vaccine capable of self-assembling into non-infectious VLP was developed. Immunization of mice demonstrated that this VLP mRNA vaccine not only elicited robust humoral immune responses with long-lasting antibody production but also effectively activated cellular immunity. In guinea pig challenge experiments, it provided immune protection comparable to that of traditional inactivated vaccines. The dual immune mechanism-simultaneously activating both humoral and cellular immunity-overcomes the limitations of traditional vaccines, making this VLP mRNA vaccine an innovative candidate for FMD control and providing a technical foundation for the development of VLP mRNA vaccines for other animal diseases. KEY POINTS: • A novel FMD mRNA vaccine that self-assembles into VLP was successfully developed. • The FMD VLP mRNA vaccine effectively stimulates both humoral and cellular immune responses. • The FMD VLP mRNA vaccine provides protective efficacy in guinea pig challenge models.
liu et al. (Mon,) conducted a other in Foot-and-mouth disease (FMD) (n=35). FMDV VLP mRNA vaccine (LNP-mP12A3C) vs. Empty liposomes or commercial O-type FMDV inactivated vaccine was evaluated on Protection rate against FMDV challenge in guinea pigs. The FMDV VLP mRNA vaccine provided a 100% protection rate against FMDV challenge in guinea pigs, comparable to traditional inactivated vaccines, while stimulating robust humoral and cellular immunity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: